Sa1343 Effects of GC7101, a Novel Prokinetic Agent on Gastric Motor Function: In Vitro Study

G A A b st ra ct s 62.5% vs. 27.3%)and severe somatic symptom severity (PHQ-15; 31.3% vs. 1.8%). Consistent with differences in overall physical and emotional function as captured by the MSIS29, MS patients with dyspepsia had a significantly worse quality of life based on the PAGIQOL (3.09 +/-0.29 vs. 4.09 +/0.11). Using bivariate analysis, the MSIS-29 subscores, HADS scores for anxiety and depression, and PHQ-15 scores significantly correlated with the PAGI-SYM total score. Using a stepwise forward regression modeling strategy, only the PHQ-15 and the MSIS 29 physical subscores independently predicted the severity of dyspepsia. CONCLUSIONS: Moderate to severe dyspeptic symptoms commonly affect MS patients and significantly impair their quality of life. Our findings suggest that dyspeptic symptom severity is principally associated with the physical rather than the emotional manifestations of MS disease.